|
Post by mnkdfann on Apr 14, 2019 7:29:37 GMT -5
I posted roughly the same thing when I first saw the ad. Award given by Big Pharma to Man kind for wasting money. Went didn't Mike and the other overpaid execs they recently hired realize that the ad was totally inneffective? I say let's try RADIO instead. Cheaper and a lot more ears, most captive in their cars for long stretches at a time. Mike, think about it and for the social media person you hired last year. Use the savings on radio ads if you want to compare effectiveness vs TV. We are not BP to use the same type stupid ad and means they do. I worked in radio for many years and can tell you there's a reason why prescription drugs aren't advertised on AM or FM. On TV you can distract the viewers from all the FDA warnings with scenes of happy people (and dogs) doing interesting things. On radio the listeners would have no distractions and would be forced to pay attention to the warnings that the drug involved could seriously harm or even kill them. As for the award the Afrezza ad received, it was for creativity, not effectiveness. I agree that it was creative, but it was terribly ineffective The award was for "Best TV Advertising Campaign". I'm sure creativity was a very large part of it, but I'm not certain other attributes of the campaign were ignored. www.mmm-online.com/mmm-awards/the-2018-mmm-awards-all-the-winners/Actually, I am feel non-creativity attributes, including effectiveness, must have been important as the entry kit says entries have to include a situation analysis, research planning, campaign objectives, strategic insight, results, etc. Creative execution is only 1 of 8 sub-headings that have to be reported. The summary is: "Campaigns that deploy clever strategy, innovative and creative execution (through state-of-the-art strategies and tactics) with demonstrable results." And circa the time the award was won, arguably the ad was effective with demonstrably positive results. MM&M specifically noted its effectiveness. www.mmm-online.com/mmm-awards/gold-tv-advertising-campaign-of-2018/"Launched in July 2017, the spot garnered more than 110,000 online views in the first few weeks. Prescription sales increased from 3,838 in Q2 2017 to 4,875 in Q3, a 27% spike. It was also the highest sales number since early 2016." FWIW, I never really liked the ad all that much.
|
|
|
Post by figglebird on Apr 14, 2019 13:53:52 GMT -5
just catching up browsing some of these later post about the investment hypothesis regarding Newer technosphere related apis...
just to give some background from my specific recollection initial substantial research prior to my first purchase and my dealings with other longs who reached out some science-based questions that I had at the time back in 2014 when I first invested...
though there were obviously many who were focused primarily on afrezzas prospects alone(though not as many as now) most that I recall talking with were equally if not more focused on the future of technosphere and the potential valuation it presented back when the market cap was around billion to a billion and a half- this was what I based and continue to base my investment around - uthr ts deal a year earlier than my earliest projection....
with respect to a frezza - there were so many obvious advantages yet so many looming signs that it would be a grind most importantly brandicourt and oppositional research. All but predicted it's inability despite qualitative components to penetrate - that same research which predicted less than 1% penetration and adoption model until pediatric approval at which point the model changed for obvious reasons... it's never in anyone's interest to be a Monday morning quarterback ivr hoped for better results and maintain some valuation in pediatric approval.
|
|
|
Post by ktim on Apr 14, 2019 14:11:50 GMT -5
just catching up browsing some of these later post about the investment hypothesis regarding Newer technosphere related apis... just to give some background from my specific recollection initial substantial research prior to my first purchase and my dealings with other longs who reached out some science-based questions that I had at the time back in 2014 when I first invested... though there were obviously many who were focused primarily on afrezzas prospects alone(though not as many as now) most that I recall talking with were equally if not more focused on the future of technosphere and the potential valuation it presented back when the market cap was around billion to a billion and a half- this was what I based and continue to base my investment around - uthr ts deal a year earlier than my earliest projection.... with respect to a frezza - there were so many obvious advantages yet so many looming signs that it would be a grind most importantly brandicourt and oppositional research. All but predicted it's inability despite qualitative components to penetrate - that same research which predicted less than 1% penetration and adoption model until pediatric approval at which point the model changed for obvious reasons... it's never in anyone's interest to be a Monday morning quarterback ivr hoped for better results and maintain some valuation in pediatric approval. I don't remember this research from that time period. Can you provide links or references for it?
|
|
|
Post by figglebird on Apr 14, 2019 14:40:27 GMT -5
The research which I have cited prior was paid for or supported by NOVO - it was not "free" as I recall and it was termed The "lazard" report.
I no longer have access to it - it did go into depth on a number of societal factors surrounding diabetes that underscore conceots like the psychological factors behind historically poor adherence - 25-30 pct actually adhere properly to prandial or supplement insulin therapy - apathy is driven by causes the derive from both the nature and durration of the disease leading to depression, denial = poor adeherence - silent killer...
it also outlyes many cultural and beaurwatic obstacles that derive from a losing war that is usually profitable to what is loosely known as the insulin mob
again it is not completely negative to the prospect of a better more flexible insulin treatment such as inhaled insulin but it does categorize that progress as more of a generational new patient initiated approach versus one that penetrates the existing population based on factors I've pointed out about that's my best recollection from what at the time was a concise assessment of the research and I did pay for to access...
|
|
|
Post by figglebird on Apr 14, 2019 14:47:03 GMT -5
also like several other institutions some that are known and some that are not widely known what kind of information has been used 4 gaming system particularly in a stock will retail has been so high all you have to do is actually look at the authors lazard and track their historical holdings with price drops and price Ascension
the sure bet component to afrezza has been utalized to draw in the type of investor who's looking for a sure bet - however many investors on the retail side as I pointed out before understand the science behind a present and not only the flexibility that it profiles with respect to inhaled insulin but its overall flexibility as a dpi additionally on that note my foolishness stems from far more I know data points that speak to the positives of technosphere with respect to the greater context of dry powder inhalation FDA approval and our position in this yet to be widespread area of inhalation
|
|
|
Post by figglebird on Apr 14, 2019 14:49:02 GMT -5
bullishness not foolishness I often have typos due to my addiction to voice to text
|
|
|
Post by falconquest on Apr 14, 2019 18:44:25 GMT -5
Sports I’m coming around to what you’re saying there. Script count evidence is impossible to ignore. But question is, who would be the right partner to help sell it? We were burned once, surely lessons were learned, but there aren’t many potential suitors out there. Would love to be a fly on the wall to hear if we are even considering it, and just as importantly, are there any takers out there with whom we’d consider partnering on it? If they co/partnered with somebody or co/ promoted they wouldn’t be giving up control. Like SENS or Dexcom. CGM + Afrezza. ( Laura could be the face for both.) Or someone that needs a diabetic presence. Someone that wants it in their tool box for corrections, or someone that just sees that inhalable insulin is the future and they better jump on the bandwagon. Abbott maybe...Also consult with Vdex on protocol. So many possibilities. What Mannkind needs is a "Flo" (Progessive Insurance) type character and I think Laura would be a good choice. They need to develop "the face of Mannkind". Somebody please help Mannkind bring some rationalization to the promotion of Afrezza. Little parachutes are BS!
|
|
|
Post by sportsrancho on Apr 14, 2019 21:28:26 GMT -5
If they co/partnered with somebody or co/ promoted they wouldn’t be giving up control. Like SENS or Dexcom. CGM + Afrezza. ( Laura could be the face for both.) Or someone that needs a diabetic presence. Someone that wants it in their tool box for corrections, or someone that just sees that inhalable insulin is the future and they better jump on the bandwagon. Abbott maybe...Also consult with Vdex on protocol. So many possibilities. What Mannkind needs is a "Flo" (Progessive Insurance) type character and I think Laura would be a good choice. They need to develop "the face of Mannkind". Somebody please help Mannkind bring some rationalization to the promotion of Afrezza. Little parachutes are BS! You wouldn’t believe how many people have mentioned “Flo” to me and I completely agree with it!
|
|
|
Post by mannmade on Apr 14, 2019 21:52:19 GMT -5
Yes I would... From a response I made on April 4th to you: They should hire a Doctor or NP to become the face of Afrezza much like Flo the spokesperson for Progressive Insurance. Promote her/him in media as an expert on Afrezza and let that person reach out one on one. If they were also a T1, even better. Have a FB page where she/he can answer questions directly as well when people have issues with dosing, insurance etc... Read more: mnkd.proboards.com/user/18/recent?page=2#ixzz5l83PQG00
|
|
|
Post by sportsrancho on Apr 14, 2019 21:55:24 GMT -5
Yes I would... Ha... oh that was you!! Good call👍🏻
|
|
|
Post by peppy on Apr 14, 2019 21:59:40 GMT -5
What Mannkind needs is a "Flo" (Progessive Insurance) type character and I think Laura would be a good choice. They need to develop "the face of Mannkind". Somebody please help Mannkind bring some rationalization to the promotion of Afrezza. Little parachutes are BS! You wouldn’t believe how many people have mentioned “Flo” to me and I completely agree with it! I think the reason "Flo" works, is the commercial is on many times everyday. Additionally, Flo/Progressive can be on a bill board. I have watched the commercial for years as we all have, however I do not use Progressive. Has anyone here changed to Progressive under Flo's influence?
|
|
|
Post by sportsrancho on Apr 14, 2019 22:03:20 GMT -5
Lol!!! No
But I like seeing the different situations they put her in :-)
|
|
|
Post by bradleysbest on Apr 14, 2019 22:53:42 GMT -5
Cycling is her passion! We need someone who will make Afrezza their passion... lol
|
|
|
Post by Thundersnow on Apr 15, 2019 2:47:58 GMT -5
What Mannkind needs is a "Flo" (Progessive Insurance) type character and I think Laura would be a good choice. They need to develop "the face of Mannkind". Somebody please help Mannkind bring some rationalization to the promotion of Afrezza. Little parachutes are BS! You wouldn’t believe how many people have mentioned “Flo” to me and I completely agree with it! Flo makes about a million dollars a year......MNKD will not pay that kind of money.
|
|
|
Post by falconquest on Apr 15, 2019 3:30:06 GMT -5
You wouldn’t believe how many people have mentioned “Flo” to me and I completely agree with it! Flo makes about a million dollars a year......MNKD will not pay that kind of money. They would if it was effective!
|
|